Lantern Pharma Inc. (LTRN) - Q1 2026 10-Q Summary
Business Context and Reporting Period
Lantern Pharma Inc. is an AI-focused biopharmaceutical company developing oncology therapies using its proprietary RADR® platform and the generative AI platform withZeta.ai. The company operates as a non-accelerated filer and smaller reporting company. This report covers the quarterly period ended March 31, 2026.
Key operational milestones include the advancement of three clinical-stage drug candidates (LP-300, LP-184, LP-284) and an Antibody Drug Conjugate (ADC) program. On May 13, 2026, the company announced plans to spin off its withZeta.ai platform into an independent business entity.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(3,329,171) | $(4,536,783) |
| Operating Expenses | $3,405,247 | $4,774,032 |
| Cash & Cash Equivalents (End of Period) | $4,917,796 | $6,377,602 |
| Marketable Securities | $1,405,057 | $5,696,386 |
| Total Liquidity (Cash + Securities) | $6,322,853 | $12,073,988 |
| Working Capital | $3,279,894 | $6,301,585 |
| Long-Term Debt | $0 | $0 |
Material Changes vs. Prior Period
- Net Loss Reduction: Net loss decreased by approximately $1.21 million (27%) compared to Q1 2025, driven primarily by a significant reduction in Research and Development (R&D) expenses.
- R&D Expenses: Decreased by $1.54 million (47%) to $1.72 million. This was due to reduced costs for research studies and materials ($1.32 million) and lower salary/benefit expenses ($246,000).
- G&A Expenses: Increased by $170,000 (11%) to $1.68 million, attributed to higher patent costs ($99,000) and salary increases ($71,000).
- Liquidity Position: Total cash and marketable securities declined significantly from $12.1 million in Q1 2025 to $6.3 million in Q1 2026. This reduction was due to the redemption of $4.25 million in marketable securities to fund operations.
- Investment Income: Interest income dropped 72% to $42,160 due to the lower balance of marketable securities held during the period.
Outlook, Risks, and Unusual Items
- Going Concern Warning: The filing explicitly states there is substantial doubt regarding the company's ability to continue as a going concern without obtaining substantial additional funding. Management projects current resources will fund operations only until approximately the middle of Q1 2027.
- Recent Capital Raise: Subsequent to the period end, on May 14, 2026, the company closed a registered direct offering raising approximately $4.4 million in gross proceeds. This included the sale of common stock and pre-funded warrants.
- Strategic Spin-off: The company plans to separate its withZeta.ai AI platform into an independent entity to access dedicated funding and potentially list separately.
- Clinical Progress: The company is focusing the LP-300 Harmonic™ trial on patients with the EGFR exon 21 L858R mutation following a Type C meeting with the FDA. Enrollment for the LP-184 Phase 1a trial is complete.
- Risks: Key risks include the inability to raise future capital, failure of clinical trials, and the early-stage nature of the withZeta.ai commercialization.
Investor Verification Checklist
- Cash Runway: Verify the updated cash runway post the $4.4 million May 2026 offering to confirm the Q1 2027 liquidity projection.
- Spin-off Details: Monitor for further details on the withZeta.ai separation, including the timeline for the new entity's listing and funding status.
- Clinical Data: Review upcoming data readouts for the LP-300 Harmonic™ trial (specifically the EGFR exon 21 L858R subgroup) and LP-184 Phase 1a results.
- Capital Needs: Assess the company's pipeline burn rate against the new capital raised to determine the likelihood of additional dilution before Q1 2027.
- Debt Obligations: Confirm the absence of long-term debt and review any new covenants attached to the recent registered direct offering.